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Cancer is the second most frequent cause of death after cardio-vascular-diseases in 
Germany [1]. Besides others, melanoma is one of the most frequent forms of cancer [2]. 
During this disease, which mostly affects women at an average age of 60, men at 66 [3], 
the patient forms black tumors on the skin [4]. The big problem occurring in the 
progression of the disease is not the cancer on the skin itself, but the high probability of 
forming metastasis [5]. Since chemotherapy being one of the common procedures to treat 
cancer is not effective in melanoma [6], it is crucial to find other approaches to influence 
the progress of the disease. 
One alternative to the well-established chemotherapy is the so called immunotherapy, 
also referred to as biotherapy [7]. This approach deals with the modification of the immune 
system or the utilization of parts of the immune system as cancer treatment [7]. The 
general idea is the targeted treatment of cancer cells without affecting healthy cells by 
boosting the immune system, thus harnessing the potential of the host immune system to 
detect and eliminate transformed cells [8]. This can be achieved for example by the use of 
antibodies selectively recognizing antigen structures on the outer membrane of the tumor 
[9]. This principle can either be used to help the immune system detecting the cancer cells 
as foreign and start attacking them or harnessing the antibody as carrier for other potent 
anti-cancer drugs to be transported to their destination. As detailed described by Robert 
O. Dillman [7], several other types of immunotherapy exist. Rituximab is targeting a 
certain protein expressed on lymphomas, Trastuzumab is affecting a tumor antigen, just to 
mention two of the immunotherapy agents that made it into clinical use [8]. To conclude, 
the advantage of immunotherapy based treatment, compared to commonly applied 
chemotherapy is the targeted effect on the cancer cells and therefore avoiding the dose-
limiting toxicity of chemotherapy resulting in lower side-effects and protection of healthy 
cells [10]. 
Also melanoma is medicated with immunotherapy. Ipilimumab is a monoclonal antibody 
conjugate which is able to interfere with the immune system, particularly blocking the 
regulatory T-cells (nTreg) [7]. This drug is approved in Switzerland since 2011 and 
commercially available as Yervoy® and is also approved by the food and drug 
administration (FDA) in the US [9]. nTreg cells have immune-suppressive properties, thus 
blocking those leads to a stimulation of the immune system [8]. Since the immune system 
misunderstands tumor cells as “self” and therefore inhibits their eradication by effector T-
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cells, excitation of this component is a promising approach to force the immune system to 
attack the malignant cells [8]. Based on this strategy, influencing nTreg cells is focused in 
this project. An inhibitor is applied, targeting the second messenger used by the cells to 
communicate and therefore control the immune-suppressive properties of nTreg-cells [11]. 
1.1 Motivation and objectives 
The aim of this work is the design and synthesis of novel adenylyl cyclase inhibitors 
containing a cleavable linker and targeting moiety for improving melanoma-specific T-cell 
responses by cAMP-mediated disarming of regulatory T-cells and therefore the 
attenuation of the progress of melanoma cancer. 
Since commonly applied chemotherapy is often ineffective in melanoma skin cancer, the 
development of new alternatives is crucial. One approach is cancer immunotherapy, 
which modifies the immune system or utilizes parts of it, for example antibodies. Those 
components can be harnessed either as marker to help the immune system to recognize 
the cancer cells or as carrier for potent anti-cancer drugs.  
In this project it is focused on a drug which is used in cancer research called NKY-80 (2-
amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone). It inhibits adenylyl cyclase (AC), the 
enzyme converting adenosinetriphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP), an important second messenger fulfilling several tasks. It is included in for 
example activating protein kinases (PKA), which are enzymes being involved in 
phosphorylation of different cellular proteins which subsequently regulate cell division, cell 
differentiation, and ion transport or ion channels. Especially cell division and cell 
differentiation are, besides their invasiveness and the ability to build metastasis, the key 
properties distinguishing cancer cells from normal cells. An intervention in these pathways 
thus is able to influence the progress of cancer. Furthermore, cAMP plays a central role in 
the suppression of the immune system. nTreg-cells control the immune system and are 
able to suppress it in order to avoid autoimmunity, allergies and anti-tumor responses as 
well [12]. Since nTreg-cells mediate their suppressive function by transferring cAMP into 
responding T-cells (resT) via gap junction intercellular communication (GJIC) and cAMP is 
a general inhibitor of T-cell growth, differentiation and proliferation, the intervention in its 
generation and dismantling can be an approach to interfere in the function of nTreg-cells 




Figure 1: Generation and degradation of cAMP and its key role as second messenger in the 
GJIC between nTreg and resT. ATP=Adenosinetriphosphate, AC=Adenylyl cyclase, 
cAMP=cyclic Adenosinemonophosphate, PDE=Phosphodiesterase, nTreg=naturally 
occurring regulatory T-cells, resT=responding T-cells 
 
During this project, the above mentioned drug NKY-80 should be coupled to a cell-
penetrating peptide (CPP). This could be accomplished by the synthesis of a linker 
bearing two functionalities. These offer the possibility to link the NKY-80 via a pH sensitive 
hydrazone bond, and on the other side making a connection with the peptide possible via 
disulfide bond. The big advantage of introducing a disulfide is the variable applications this 
moiety can be used for as displayed in Figure 2.  
 
 
Figure 2: Structure of the linker (orange) coupled to NKY (black) via hydrazone. Additional 
capability to bind different carriers (blue): i) CPP=cell-penetrating peptide, ii) FA=folic acid, 
iii) AB=antibody by forming a disulfide bond 
 
NKY-80 itself lacks in potency which is why it requires the coupling to a carrier, but this 
also needs to fulfill the targeting demand. During this project, NKY-80 should be coupled 
to a cell-penetrating peptide via a linker, which will also be synthesized within this project. 
As described, cAMP is involved in miscellaneous pathways within the body, making a 
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systematically administration of NKY-80 impossible. Although the coupling to a CPP 
should increase the uptake level of the drug into a cell, it would not improve the selectivity 
of the drug. But since melanoma is represented on the skin, a direct injection into the 
tumor could be possible, bypassing the selectivity problem. In order to also treat the 
metastasis occurring frequently when suffering from skin cancer, a targeting application is 
also necessary. This could be achieved by coupling NKY-80 via the introduced linker to 
either an antibody or a folic acid, since both act via receptor mediated endocytosis [14, 
15]. To target nTreg-cells the conjugate with antibodies (AB), for targeting melanoma cells 
the folic acid conjugate could be applied. 
The synthesis of folic acid containing NKY-80 will be carried out during this project. Since 
quickly dividing cells have a higher consumption and need of folic acid for reproducing 
themselves, they express more folic acid receptors on their cell membrane than “normal” 
cells do [16]. This fact can be exploited to target these quickly dividing cells, thus cancer 
cells [17]. In order to attach the linker to folic acid, a thiol has to be introduced into the 
vitamin, which should be achieved by the conversion with 2-aminoethanethiol. 
In brief, a linker bearing a hydrazine and an activated thiol will be synthesized in a two-
step reaction. An adenylyl cyclase inhibitor called NKY-80 will be attached by the 
formation of a hydrazone bond. On the other side the thiol offers the possibility of coupling 
either a cell-penetrating peptide or a folic acid moiety, which will be both performed during 





2 General part 
2.1  Cancer and Melanoma 
2.1.1 General procedure of treating cancer 
About 26 % (221.500 people) died because of cancer in Germany in 2011, thereof 
119.755 men and 101.836 women. The former suffer from cancer affecting the intestinal 
tract (32 %) or the respiratory system (26 %). Also females die most commonly due to 
intestinal cancer (30 %), followed by breast cancer (18 %). Siegel et al. report that 5 % of 
all new diagnoses of cancer are accounted for melanoma in 2012 in the US. The mortality 
rate increased from 8790 in 2011 to 9180 in 2012. Due to the general permanently 
increasing number of cancer patients this means, that 1 of 3 women and 1 of 2 men will 
develop cancer during his or her lifetime in the US Thereof 7 % of both, men and women, 
are affected by melanoma [18-20]. 
Three different procedures which are mainly applied in the treatment of cancer are 
available, surgical excision, irradiation and drug therapy, also called chemotherapy. 
Depending on the type and the progress of the disease, the patient is treated in a different 
way with one of the above mentioned approaches or combinations of them. The big 
difficulty in cancer therapy is the differentiation between malignant and healthy cells.  
In case of melanoma the affected skin part is excised. Depending on the progress, the 
size of the removed area around the mole varies. Furthermore, the closest located lymph 
node can also be eliminated [21].   
Additionally, chemotherapy is applied to melanoma, on which patients do not respond in 
every case [6]. Therefore immunotherapy is a promising alternative to treat melanoma. In 
immunotherapy the immune system is activated to eliminate or attenuate the progress of 
the tumor [7, 8]. Different approaches exist, focusing on different pathways within the 
tumor cell.  
The standard chemotherapy agent used for the treatment of melanoma is Dacarbazine 
(DTIC). It is the only one being approved by both, the FDA (food and drug administration) 
and the EMA (European medicines agency) [22]. Dacarbazine is a monofunctional 
triazene alkylating the bases of the DNA when administered to a cell which stops the 
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proliferation [23]. However, DTIC has shown objective responses for only 15.3 % and 
complete response rates for 4.1 %, tested with 3356 patients in more than 20 studies [24]. 
Besides chemotherapy, melanoma is treated with immunotherapy agents like high-dose 
interleukin-2 (HD IL-2) or Interferon-α (IFN-α) [25]. Drawbacks of these drugs are also the 
low response rates, as well as the high toxicity especially in high dose application and the 
associated side-effects. In order to optimize the efficiency, INF-α was pegylated and 
combinations of chemotherapy and immunotherapy as well as mulitdrugchemotherapy 
was tested in clinical trials. Approaches including IL-2 and IFN-α led to higher responses, 
but associated with this, toxicities also increased [25].  
Vemurafenib, Ipilimumab and Tremelimumab are immunotherapy agents containing a 
monoclonal antibody targeting different pathways within a tumor cell in order to stop the 
progress. Vemurafenib strongly and selectively inhibits mutant BRAF being part of the 
RAS/RAF/MEK/ERK (MEK=mitogen-activated protein kinase, ERK=extracellular-signal 
regulated kinase) pathway. This pathway is responsible for the conversion of stimulatory 
signals of growth factors by binding to their cognate receptors on the outer membrane, 
resulting in activation of several cytoplasmic and nuclear substrates. A genetic mutation in 
the BRAF gene (called V600E mutation, valine to glutamic acid substitution at codon 600) 
which is very common in melanoma, leads to significant activation of ERK and therefore 
supporting cell proliferation and survival. Vemurafenib is just effective for patients 
suffering from BRAFV600E mutation, but even after successful cure, patients experience 
tumor recurrence or develop resistance against the drug. Consequently, multi- instead of 
monodrug therapy is suggested [26].  
Ipilimumab and Tremelimumab target cytotoxic T-lymphocyte antigen 4 (CTLA-4), a 
membrane protein on T-cells where it acts as a negative regulator. The drugs are capable 
of increasing T-cell activity by blocking of negative regulation signals. Thus, they inhibit 
the CTLA-4 protein which down regulates the immune system and therefore antitumor 
immunity is supported. Ipilimumab bears the benefit of improving the 1-year and 2-year 
survival rates, which has been tested with 676 people by Hodi et al in 2010, but it also 
reaches low response rates when used as single therapy [27]. Tremelimumab did not lead 




2.1.2 Genesis of a cancer cell 
Due to mutations in the DNA, a normal cell can become a cancer cell. This can have 
several reasons like being inherited, acquired or as a result of exposure to carcinogen 
substances like tobacco or as an effect of viruses. Furthermore, the activation of proto-
oncogenes (control cell division, apoptosis and differentiation) to oncogenes (induce 
malignant change by viral or carcinogen action) as well as the inactivation of tumor 
suppressor genes (anti-oncogenes) higher the potency of contracting cancer. The 
characteristics that distinguish cancer cells from normal cells are uncontrolled 
proliferation, dedifferentiation and loss of function, invasiveness and the ability to form 
metastasis. Besides that, a tumor consists of different types of cells which make a 
successful therapy difficult. About 5 % of the cells are dividing cells, which can easily be 
affected by chemotherapy. In addition to that there are cells which do not divide anymore 
but be a part of the tumor, bearing no problem because they cannot harm the body 
anymore. But the biggest risk comes from the resting cells, which are not dividing 
anymore, thus are not affected by the common therapy which affects the cell division in 
most cases, but do still have the possibility to start proliferation again [29]. 
In case of melanoma the highly malign tumor is coming from the melanocytes. It forms 
metastasis already in early stage in the lymph nodes and haematogenic. The quick 
invasion of melanoma cells into the thin lymph tissue or upper dermis and therefore early 
metastasis is explained by the fact that benign and malign melanocytes do not grow in cell 
groups and do not form intracellular bridges [21]. The genesis includes several steps 
which can undergo a linear or non-linear sequence [5]. The detailed correlation is 
explained by Villanueva et al. [30].  
2.2 Signal transduction to influence the regulatory T-cells 
cAMP is an important second messenger bearing miscellaneous functions. It is generated 
from adenosinetriphosphate (ATP) by adenylyl cyclase (AC) and degraded to 5’-
adenosinemonophosphate (5’-AMP) by phosphodiesterase (PDE).  
Mammals express ten different isoforms of AC, which are membranous bound enzymes 
being activated by binding of hormones and neurotransmitters to their G-Protein-coupled 
receptors (GPCR) [31]. The catalytic core of AC is made up by two cytosolic, 
pseudosymmetrically domains (C1 and C2) with six predicted helices each. At their 
interface they form the catalytic site and the regulatory diterpene site. The different 
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isoforms are differentially expressed in different cells and tissues, leading to the 
assumption they having specific (patho)physiological functions [32]. The stimulation and 
influence of AC is displayed in Figure 3.  
 




In general ACs catalyze the generation of cAMP, which activates the protein kinase A 
(PKA). This in turn controls the function of several cellular proteins by regulating protein 
phosphorylation. Furthermore, enzymes involved in energy metabolism, cell division, cell 
differentiation, ion transport and channels and contractile proteins in smooth muscle are 
influenced and modulated by PKA [29]. Besides this, cAMP is crucial for the maintenance 
of the immune system. nTreg-cells are a thymus derived subset of T-cells which are of 
capital importance for preventing autoimmunity [8]. They transfer cAMP via gap junction 
intermolecular communication (GJIC) to resT, resulting in inhibition of IL-2 gene 
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expression [12], which means that the immune response is decreased, since IL-2 is 
essential for proliferation and differentiation of T-cells [34]. The exact underlying molecular 
mechanism still remains unclear, but Bodor et al. [35] suggest, that a competition between 
transcriptional repressor (ICER) and transcription factor (CREB, cAMP response element 
binding protein) results in decreased IL-2 expression. 
To sum up, cAMP expression results from activation of GPCR of AC by hormones or 
neurotransmitters [29]. This leads to immune suppression via GJIC of nTreg to resT 
mediated by cAMP [36]. Consequently, modulation of the generation and degradation of 
cAMP is a promising approach to shape the immune response.  
2.3 Characteristics of the non-nucleoside adenylyl cyclase 
inhibitor NKY-80 
NKY-80 (2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone), displayed in Figure 4 is 
a non-nucleoside AC inhibitor [37]. According to the interrelation explained 
 
Figure 4: Structure of NKY-80 
 
in chapter 2.2 it allows the regulation of the suppression of the immune system by 
attenuating the amount of expressed cAMP. NKY-80 is capable to interfere with the P-site 
(catalytic side) of the AC, which means binding to the same site as the substrate ATP [32]. 
However, the mode of inhibition is either un- or non-competitive as shown by kinetic 
analysis [38]. The inhibitor was discovered after virtual screening of more than 850,000 
compounds on the basis of the pharmacophore analysis of AC and P-site ligands [37]. 
The focus of the initially research was put on inhibitors of the catalytic side, resulting in 
nucleoside-based compounds like THFA (9-(tetra-hydro-2-furanyl)-9H-purin-6-amine), 
also known as 9-THF-Ade [32]. These moieties bear a big disadvantage, the risk of 
interfering in DNA synthesis due to their structural similarity to nucleosides being the 
building blocks for the genetic material [32]. Unlike other studied compounds which have 
been listed by Seifert et al. in 2011, NKY-80 carries the properties of being a catalytic side 
inhibitor not containing an adenosine ring. Besides this drug, there is only MDL, also being 
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an AC inhibitor which is used for cell studies [39] holding the same features. In contrast to 
that, one drawback of NKY-80 is the lack in potency. IC50 values achieved in an AC assay 
in the presence of Mg2+ gave the following results displayed in Table 1. 
Table 1: Overview of IC50 values of NKY-80 for three different isoforms of adenylyl cyclase, 
reported by two different references 
 IC50 AC2 IC50 AC3 IC50 AC5 
Iwatsubo et.al. [40] 2.6 mM 230 µM 15 µM 
Onda et.al.[37] 1.7 mM 130 µM 8.3 µM 
 
Due to the fact that this compound is of low potency, it is difficult to obtain fully saturated 
concentration/response curves for precise calculation of IC50 values explaining the 
deviation between the two sources [37]. 
2.4 Cell-penetrating peptides 
Cell-penetrating peptides (CPP) are a group of peptides being capable of crossing the 
cellular membrane [41]. Since the first CPP, the transcription-transactivating (Tat) protein 
of HIV-1 has been discovered by Frankel and Pabo in 1988 [42], they are utilized in a 
diversity of applications like being attached to siRNA, nucleotides, small molecules, 
liposomes or proteins beyond others [43, 44], thus in case of a drug being coupled to a 
CPP a drug-delivery-system (DDS) is formed. Due to the difficulties in drug delivery, CPPs 
are a promising approach to overcome general problems in the administration of 
pharmacologically active substances [45]. The requirements for a drug being applied to an 
intracellular target site are oppositional to each other. They need to be both polar enough 
to ensure an easy administration and equal distribution and also show hydrophobicity to 
allow the penetration of the lipid bilayer of the cell [46]. This is the reason why several 
drugs fail to make it into clinical trials. To circumvent the necessity of extensive 
modification and fine-tuning in their final structure, connection to a CPP offers a promising 
alternative to ensure a good bioavailability [46]. In this way the potential therapeutic space 
can be expanded due to increased availability of targets [47]. CPPs, also referred to as 
protein-transduction domains (PTD) [44], typically consist of 5-30 amino acids, that can be 
divided into two groups depending on their binding properties. On the one hand are 
peptides requiring chemical linkage with the drug and on the other hand the ones forming 
stable, non-covalent complexes with the cargo [48]. Furthermore, they can be sorted 
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depending on their amino acid composition. CPPs containing several arginine or lysine 
residues represent the group of cationic CPPs. In contrast to that, also anionic or neutral 
sequences are possible. All of them vary in hydrophobicity and polarity, resulting in 
different modes of uptake. Furthermore, the level of uptake is dependent on diverse 
parameters like cell line, the cargo and the way it is attached to the CPP [49-52]. In 
general, different mechanisms of cell penetration are discussed extensively [53], as 
displayed in Figure 5. 
 
 
Figure 5: Different possible mechanisms of cellular uptake for cell-penetrating peptides [54] 
 
Endocytosis and direct translocation are the major mechanisms explaining how 
substances are delivered into the cell. Endocytosis can further be split into clathrin-
dependent endocytosis (CDE) and clathrin-&caveolin independent endocytosis (CDI).  
In CDE, the cytoplasmic domains of plasma membrane proteins are recognized by 
adaptor proteins and packaged into clathrin-coated vesicles that are brought into the cell 
[55]. Due to the involved surface receptors this is the most selective form of endocytosis 
by that a CPP can enter a cell. 
CDI is additionally divided in different forms, such as macropinocytosis, caveolae and/or 
lipid raft-mediated endocytosis. Macropinocytosis involves cell surface ruffling, providing a 
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relatively large cavity and thereby offer an efficient way for non-selective endocytosis of 
solute macromolecules [56]. Next, the formed macropinosome is carried along 
microtubules inside the cell [55]. In opposite to that, caveolae, a special form of lipid rafts, 
is mediated by a protein called caveolin, which is suggested to be responsible for stability 
of the membrane and shape of caveolae. Lipid rafts are microdomains present in the 
plasma membrane consisting of a combination of glycosphingolipids and protein 
receptors, being able to float freely in the membrane bilayer [57]. This mechanism is not 
well characterized and also referred to as nonclathrin/noncaveolar endocytosis [55]. 
In contrast to the endocytosis mediated delivery is the direct translocation. This 
mechanism in turn is divided in the carpet model and the barrel-stave model, differing in 
the organization of the membrane phospholipids. The carpet model describes an 
extensive reorganization of the previously mentioned membrane, whereas the barrel-
stave model applies the formation of transient pores, resulting in a disturbance of the lipid 
bilayer. However, this model is not likely to occur for high molecular weight conjugates 
[58]. 
To sum up, all these pathways differ in their uptake mechanism but share a common 
result: extracellular substances are internalized into the cell after release of the plasma 
membrane by means of lipid vesicles [59]. Furthermore, they are harmless to the cells and 
do not destabilize the membranes or loose cellular integrity [58].  
Whatever the case, the mechanism of delivery is strongly dependent on different 
parameters like the composition of the peptide or the cargo. With respect to this 
knowledge and experience, which physicochemical properties favor one mechanism over 
another, it will be possible to generate peptides following a certain uptake mechanism 
relevant to their application [54]. 
During this project, a peptide with the sequence Cys-Gly-Gly-Trp-Arg8 has been used. 
Since octaarginin based proteins are well explored, it is assumed that this peptide is taken 
up by the cell via endocytosis instead of direct penetration. But still, the exact mechanism 




Figure 6: Different cellular uptake mechanisms in the case of oligoarginines depending on 
the chain length [60]. R4 and R10 describe the amount of repeated arginines, R4B and R10B 
stands for a different conjugation in contrast to R4 and R10. 
 
As explained above, different endocytosis pathways are possible, like clathrin or caveolin 
coated vesicles, as well as macropinocytosis for bigger molecules consisting of longer 
arginine chains. Whatever uptake mechanism is carried out, the conjugate arrives inside 
the cell either as lysosome or is released into the cytosol. 
Due to the change from physiological pH to acidic conditions in endosomes (pH 5.0-6.5) 
and lysosomes (pH 4.5-5.0) [10], the cargo can be cleaved from the CPP depending on 
the linkage. As in this project a hydrazone moiety is applied, which will be hydrolyzed at a 
pH lower than 6 [61]. This approach has already been reported by Kaneko et al. [62] for 
coupling a drug call doxorubicin to the linker applied in this project. 
Beyond the beneficial properties of CPPs, there is also one big drawback being the 
imprecision in targeting, meaning all cells can be penetrated without distinction [44]. 
Nevertheless, cell-penetrating peptides offer a good strategy to deliver different types of 
cargos into cells and in case of drugs thereby reducing the applied dose and thus lowering 
the side effects.  
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2.5 Folic acid 
Folic acid (FA) is an essential vitamin which is involved in DNA synthesis and therefore in 
cell proliferation [29]. Its structure is displayed in Figure 7 . 
 
Figure 7: Structure of folic acid 
 
It is synthesized by a couple of microorganisms before it is consumed by humans with 
their diet. After the uptake, the substance is reduced to active metabolites, whereof 5-
Methyltetrahydrofolate is the most important one. Since the metabolites act as coenzymes 
during the transfer of carbon-moieties (e.g. methyl groups), they play a significant role in 
the synthesis of DNA-bases [63]. Due to this fact, quickly dividing cells require a higher 
amount of folic acid than normal cells do. This circumstance can be harnessed as 
targeting approach in cancer therapy, since cancer cells proliferate fast. To absorb the 
folic acid into the cell, special folic acid receptors are present at the cell membrane. 
Because quickly proliferating cells have a higher need of folic acid, they over express the 
corresponding receptor [16].  
The absorbance mechanism of folic acid into the cell still remains unclear. However, it is 




Figure 8: Uptake mechanism of folate conjugates via folate receptor [16] 
 
According to this relation, anti-cancer drugs are coupled to folic acid derivatives to achieve 
a higher concentration of the drug inside the cell and without affecting healthy cells [17]. 
This procedure has been successfully applied for nanoparticles, protein toxins, anti-T-cell 
receptor antibodies, interleukin-2, chemotherapy agents, g-emitting radiopharmaceuticals, 
magnetic resonance imaging contrast agents, liposomal drug carriers and gene 
transfervectors [14]. The conjugation with folic acid bears several benefits as its small 
size, stability against temperatures and pH values making it capable for chemical 
modification, inexpensiveness, non-immunogenicity and its high affinity for binding to the 
folic acid receptor [64]. 
The figure shows the uptake of a folate-drug conjugate. First, the folate moiety is 
recognized by the folate receptor present at the membrane of the cancer cell. Next, an 
endosome is formed implicating the ligand-receptor complex. The endosome is 
transported to the inside of the cell, where it releases the folate-drug conjugate, which is 
decomposed resulting in free, uncoupled drug molecules. As displayed in the picture 
ambiguous, the endosome does not break within the cell. In case of the NKY-FA 
conjugate (conjugate of NKY-80 with folic acid), the hydrazone bond linking them together 
breaks within the acidic conditions inside the endosome, leading to release of the drug 
which is then small and hydrophobic enough to pass the endosome bilayer membrane. 
This promising targeting approach is assumed to reduce the dose of the drug on the one 
hand and on the other hand limiting the side-effects. 
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3 Results and discussion 
In order to influence the immune system to eradicate tumor cells, two final products have 
been synthesized during this project containing the adenylyl cyclase inhibitor NKY-80. On 
the one hand, it has been coupled with a cell-penetrating peptide to increase the cellular 
uptake since NKY-80 lacks in potency [37, 40]. The conjugate of CPP and NKY-80 could 
be applied by direct injection into the melanoma. On the other hand, NKY-80 was 
connected to folic acid. The second approach was done due to the folic acid receptors 
being present on cell membranes especially in higher amount on quickly dividing cells like 
melanoma cells. This fact can be used as targeting approach helping to decrease the 
applied dose of the drug and based on the selectivity of the folic acid to its receptor 
lowering the side-effects meaning affecting healthy cells. As displayed in Figure 9, a linker 
was synthesized bearing a hydrazine to couple the drug and furthermore offering a 
disulfide making it reactive against several possible coupling partners. 
 
 
Figure 9: Structure of the linker (orange) coupled to NKY-80 (black) via hydrazone. 
Additional capability to bind different carriers (blue): i) CPP=cell-penetrating peptide, ii) 
FA=folic acid, iii) AB=antibody by forming a disulfide bond 
 
A linker is necessary to bind NKY-80 to different carriers. The linker synthesized during 
this project, 3-(2-pyridyldithio)propionic acid hydrazide (PDPH), has been used for the 
coupling of different moieties, e.g. as described by Ansell et al. in 1996, conjugating an 
antibody with a liposome [65] or Zara et al. making immunoconjugates with the same 
linker [66]. It benefits of the presences of both, a hydrazine and an activated thiol. The first 
can form a hydrazone by reacting with a carbonyl-group as it is present in NKY-80. The 
activated thiol makes the coupling to other moieties offering a thiol possible, as in this 
project the conjugation with a cell-penetrating peptide and a modified folic acid, which are 
necessary to carry the drug into cells. Additionally, with this linker it would be possible to 
attach the drug to an antibody. The hydrazone bond ensures the release of the drug after 
internalizing into a cell. The internalization is mainly achieved by receptor mediated 
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endocytosis, thus resulting in the assumed formation of endosomes or lysosomes. Both 
bear an acidic environment within their compartment leading to cleavage of the hydrazone 
bond [61], thus free NKY-80 is present, which can then pass through the compartment 
into the cytosol. In case of another transportation pathway referred to as direct 
translocation, the drug-delivery-system ends up directly in the cytosol thus no change in 
pH will occur. However, the cytosol contains disulfide cleaving glutathione. Glutathione is 
a tripeptide present in almost all cells of the body, acting as antioxidants and disulfide 
reducing agent [67]. Consequently, the release of the drug is guaranteed, independent of 
the uptake mechanism into the cell, thus either the hydrazone or the disulfide is cleaved. 
Furthermore the bonds are stable within the blood stream to ensure the bioavailability at 
the point of action [68]. 
Chapters 3.1-3.4 discuss the single steps of the synthesis and a complete overview about 




Figure 10: Complete overview about the performed synthesis 
 
3.1 Linker synthesis 
A linker containing two functionalities in order to be capable for coupling two different 
compounds was synthesized in a two-step reaction as displayed in Figure 11. 
 
Figure 11: Two-step synthesis of linker bearing hydrazone and disulfide functionality 




The first step reaction was carried out as described by Delius et al. in 2010 [69] resulting 
in a yield of 98 % and a purity of 95 %. The product was used without further purification 
for the second reaction step which was carried out in accordance to van der Vlies et al. in 
2010 [70] and in house experiences. In opposite to the described procedure the product 
was purified using column chromatography, resulting in a slightly yellow solid with a yield 
of 74 %.  
The synthesis of the cross-linker has been reported in literature, but using another 
pathway [66], starting from N,N'-bis(tert-butyloxycarbonyl)-L-cystine dimethyl ester forming 
the bis(hydrazide) by reacting with hydrazide. After protection of the hydrazide, the 
tetrakis-(BOC)cysteine derivative was formed which was then reduced to obtain the 
cysteine derivative. Next, the product was treated with 2,2’-dipyridyl disulfide to achieve 
the desired linker. The advantage of the reactions used in this project is the length, being 
short with two steps in opposite to 5 steps as reported. As reported by Zara et al. [66], the 
conversion with hydrazine yielded 87 %, the formation of the disulfide 53 %. 
Consequently, the conditions applied in this project do not only reduce the amount of work 
but also result in higher yields. 
The structures of both obtained products (1 and 2) were confirmed using NMR 
spectroscopy (1H and 13C) and ESI-ToF-MS. For the first product, it is difficult to 
distinguish whether the disulfide or the free thiol has been formed. Directly after the 
synthesis of 1 has been performed, 1H-NMR spectra were recorded in different solvents 
(DMSO-d6 and CDCl3). In both cases it was not clear if the free thiol is present due to the 







H-NMR spectrum (250 MHz, CDCl3, 298 K, reference: residual solvent CHCl3) of 3-
mercaptopropanehydrazide (1) 
 
At a shift of around 3.8 ppm a hump is visible in the spectrum, possibly bearing signal 1 
and 5. In comparison with literature data of 3-mercaptopropanehydrazide (1), the reported 
shifts for the CH2-groups fit to the ones recorded. The compared spectra were measured 
in CDCl3 [69]. The presence of the disulfide would influence the CH2-S-group leading to a 
bigger shift difference between the two CH2-groups (comparison with methyl-3-
mercoptopropanoate and dimethyl 3,3'-dithiodipropionate, [71]). But since the shifts of the 
recorded and reported spectra fit, the presence of the free thiol is assumed. Additionally, 
for the two reference compounds, the shifts for carbons 3 and 4 vary when a disulfide is 
formed. In case of a free thiol, 4 can be assigned to a peak at around 20 ppm, 3 at around 
38 ppm. After formation of a disulfide, both carbons would give peaks at around 33 ppm. 
The 13C-NMR spectrum measured for compound 1 shows peaks at 20 ppm and 37 ppm, 
proving the presence of the free thiol. 
The ESI-ToF-MS measurement of 1 was performed after some days of storage in the 
fridge while the high viscous oil change into a partly crystal structure. The mass showed 
the formation of disulfides. However, this aggregation can either have happened during 
storage or measurement. Nevertheless, the next reaction step could be carried out without 
problems.  
The structure of 2 was confirmed by 1H-NMR spectroscopy as displayed in Figure 13 as 






H-NMR spectrum (250 MHz, DMSO-d6, 298 K, reference: residual solvent DMSO) 
of product 2 confirming the desired structure 
 
This NMR spectrum shows the four protons of the inserted pyridine moiety (number 5-8). 
The peaks 1-4 represent the groups that have already been present in the spectrum 
before, but after disulfide formation the CH2 groups have shifted to low field.  
This spectrum proves the successful reaction. This leads to the assumption, that 1 has 
been present as free thiol making the conversion to 2 possible. During the reaction 2-
pyridinethiol is formed which tautomerizes to 2-pyridinethion, displayed in Figure 14, a 
yellow and stable molecule. The formation of this side-product is observed during reaction 
monitoring using TLC. In case of 1 has formed a disulfide, on the one hand the yellow 
compound could not be seen, and on the other hand the driving force of the reaction, the 
formation of the stable 2-pyridinethion, is lost. Although it could be thought about a 




Figure 14: Tautomerism of the side product 2-pyridinethiol formed during the second step 
of the linker synthesis 
 
The introduction of the 2-pyridinethiol group into the linker activates the thiol and being 
therefore beneficial for the following conjugation since it is additionally a good leaving 
group due to the above mentioned tautomerism. 
The incomplete reaction proven by TLC led to the necessity of purification using column 
chromatography (solvent: EtOAc:MeOH 9:1, silica gel, pore size 0.04-0.063 mm). This 
process can simply cause loss of product due to mixed fractions. Furthermore loss during 
imprecise work can explain the yield of 74 %. Nevertheless, this process results in a pure 
product as also seen after recording an HPLC chromatogram showing 91 % purity. 
ESI-ToF-MS spectrum displayed in Figure 15 shows the molecule peak as well as 





Figure 15: ESI-ToF-MS (positive mode) measurement of product of second step linker 
synthesis proving the structure by showing the protonated molecule peak, the 
corresponding sodium adduct, aggregates of two and three molecules as sodium adduct 
and one fragment as protonated and sodiated ion 
 
The experimental and theoretical masses are displayed in Table 2. Furthermore the 
deviation in Da, as well as in percentage is shown. ESI-ToF-MS is a precise method 
giving results with an accuracy of about m/z ± 0.1, consequently the obtained results are 
satisfying and thus prove the correct mass of the product. 
Table 2: Comparison of experimental and theoretical masses measured with ESI-ToF-MS for 





Δmass [Da] Deviation [%] 
[M+H]+ 230.06 230.04 0.01 0.01 
[M+Na]+ 252.04 252.02 0.01 0.01 
[2M+Na]+ 481.09 481.05 0.01 0.01 




The presence of the protonated molecule [M+H]+ and its corresponding sodium adduct 
[M+Na]+, besides the aggregates [2M+Na]+ and [3M+Na]+ confirms the structure of this 
reaction. Additionally, no peak with an m/z ratio of 120 is detected, proving the absence of 
1, the same applies for aldrithiol having an m/z ratio of 220 which is not identified within 
the above shown spectrum. However, the other peaks present in the spectrum cannot be 
assigned. 
To sum up, both reactions led to the desired products which are confirmed by NMR 
spectroscopy and ESI-ToF-MS, furthermore the positive reaction within the next step 
proves the structures. The successful performances of these two reactions result in the 
linker being able to couple the drug to different carriers. 
3.2 Coupling of linker to NKY-80 
The linker, bearing a hydrazine moiety can be attached to the carbonyl-group NKY-80 as 
displayed in Figure 16.  
 
 
Figure 16: Coupling of linker to NKY-80 via hydrazone formation by reaction of hydrazine 
and keto-group 
 
To find out the right conditions, the reaction was carried out three times. It was started 
with a ratio of 2:1 (2:NKY-80) and acetic acid as catalyst, since the TFA, which is used in 
literature [62], is a strong acid capable of cleaving the hydrazone bond. Since NKY-80 
was not consumed completely, the equivalents of 2 were increased to 3, yielding in 57 %. 
During the second try, the reaction was additionally catalyzed with TFA, resulting in an 
increased yield of 62 %. When catalyzing the reaction with TFA only and using a ratio of 
3:1 for 2:NKY-80, the reaction yielded 67 %. 
25 
 
This conditions are similar to as reported by Kaneko et al. in 1991 [62] who used 
Doxorubicin in methanol. Since this exact reaction using NKY-80 has not been reported in 
literature, there is no reference to compare the yields. However, Kaneko et al. reported a 
yield of 90 % for the coupling to another drug called doxorubicin also via the formation of a 
hydrazone to the same linker as applied in this project. The loss can happen due to 
imprecise working. 
During the formation of the hydrazone bond two isomers, E and Z, can be formed, which 
gets obvious when looking at the mechanism displayed in Figure 17. 
 
Figure 17: Formation of the hydrazone bond during the coupling of NKY-80 to linker 
 
The lone pair of the hydrazine attacks the partial positive carbonyl atom of the NKY-80. 
After the formation of the nitrogen-carbon bond a negatively charged oxygen remains, 
taking up two protons which are acting as catalyst. Next, water is split off, resulting in 
nitrogen-carbon double bond carrying the positive charge. In this step it is decided 
whether the E or Z isoform is formed. By removal of the catalyst proton, a neutral 
molecule bearing a hydrazone bond is formed.  
The assumption of two isomers is confirmed by NMR spectroscopy. As displayed in 
Figure 18, the 1H-NMR spectrum shows two peaks for one proton in several positions in 




Figure 18: Cut-out of 
1
H-NMR spectrum (700 MHz, DMSO-d6, 298 K, reference: residual 
solvent DMSO) of the conjugation between linker and drug (3) for structure prove 
 
The isomeric ratio is determined by integration of the peaks in circle in Figure 18 resulting 
in 0.4/0.6. Peaks belonging to proton 2’ and 7 are highly influenced by the 
stereochemistry, resulting in higher shift differences. Peaks of proton 1, 2, 3 and 8 
(dashed circles) are still influenced resulting in double peaks but giving almost the same 
shift. The influence gets obvious when comparing this spectrum with the one of unreacted 
NKY-80 where these double peaks do not appear. To sum up, the stereochemistry affects 
the whole molecule, however, due to overlapping, the stereochemistry cannot be proven 
for peaks of the pyridine ring and the ones appearing in high field. Furthermore, it is not 
possible to elucidate which peaks belong to which isomer. 
An H-N correlation measurement further confirms the presence of E and Z isoforms. The 
NH group of the hydrazone bond is strongly influenced by the stereo chemistry inside the 
molecule. Consequently, two peaks can be assigned for the coupling between nitrogen 
and proton, which have almost the same shifts and together result with an area under the 
curve (AUC) of 1 in integration. 
13C-NMR spectroscopy, as well as 2D measurements were carried out to confirm the 
structure (data not shown). 
TLC is used to monitor the reaction. In the reaction mixture, two spots are detected, 
referring to 2 and the new product. NKY-80 was completely consumed since no third spot 
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referred to NKY-80 is visible in the reaction mixture anymore. Although it has been 
converted completely, the reaction yielded 67 %. Compound 2 has been used in access 
explaining the presence of that spot in the reaction mixture. The elucidation if the new 
spot belongs to the desired product was obtained by different NMR measurements (see 
above), as well as ESI-ToF-MS and MALDI-ToF-MS. Both methods were applied to be 
absolutely sure to have the right product since this is the starting point for the following 
formation of the final products. 
Figure 19 shows the ESI-ToF-MS spectrum. 
 
Figure 19: ESI-ToF-MS (positive mode) of NKY-linker conjugate (3) 
 
The MALDI-ToF-MS spectrum shows the same masses (data not shown). Besides the 
protonated and sodiated molecule peaks ([M+H]+, [M+Na]+), double and triple aggregates 
are also visible ([2M+H]+, [2M+Na]+, [3M+H]+). The disulfide bond is assumed to break 
during the measurement, but no fragment with a corresponding m/z of 331 can be 
detected. However, a significant peak at 330.09 marked as [F1+H]+ is identified, which 
can be explained with a double bond formation between sulfur and carbon as also 
displayed within Figure 19.  
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Table 3 shows the experimental and theoretical masses for the assigned peaks, as well 
as their deviations from each other in Da and percentage. All peaks referred to the 
product show a very low deviation below 0.01 % and therefore prove the presence of the 
desired product.  
Table 3: Comparison of experimental and theoretical masses measured with ESI-ToF-MS for 






Δmass [Da] Deviation [%] 
[M+H]+ 441.11 441.12 0.01 0.002 
[M+Na]+ 463.13 463.10 0.03 0.007 
[2M+H]+ 881.27 881.23 0.04 0.005 
[2M+Na]+ 903.25 903.21 0.04 0.004 
[3M+H]+ 1321.40 1321.34 0.06 0.005 
[F1+H]+ 330.09 330.10 0.01 0.002 
 
To conclude, NKY-80 was successfully coupled to the previous synthesized linker. Thus 
this conjugation now offers the opportunity of coupling the drug to either a cell-penetration 




3.3 Coupling of NKY-80-linker to a cell-penetrating peptide 
The NKY-linker conjugate, bearing a disulfide group can be attached the free thiol of 
cysteine being part of a cell-penetrating peptide as displayed in Figure 20.  
 
Figure 20: Coupling of linker-drug conjugate (3) to cell-penetrating peptide 
 
The reaction was carried out as in a mixture of DMF and DPBS (Dulbecco’s phosphate 
buffered saline) referring to in house experiences, resulting in a yield of 48 %. As 
explained for the formation of the linker in chapter 3.1, the driving force of the reaction is 
the formation of the side-product 2-pyridinethion pushing the equilibrium occurring during 
disulfide exchange to the product side. The buffer is necessary to ensure a constant 
neutral pH to avoid cleavage of the hydrazone bond. 




Figure 21: Progress of the coupling between NKY-80 and CPP measured by HPLC. X-axis: 
retention time in minutes, Y-axis: intensity measured with UV detector at 280 nm in atomic 
units 
 
Immediately after mixing the two starting materials, a sample was taken. The according 
measurement is displayed in the upper line in Figure 21. It shows the starting material 3 
and already formed product 4. This shows the speed of the reaction, consequently, after 
45 minutes the starting material is almost completely consumed. After 2 hours the ratio 
has not changed anymore thus purification using preparative HPLC was subsequently 
performed to remove the side product formed during the reaction, 2-pyridinethion and 
unreacted starting material. The free peptide cannot be detected in HPLC at the applied 
wavelengths, however 1H-NMR of the product confirms the purity of the product and the 
absence of any starting material or side product.  
Integration of the 1H-NMR spectrum displayed in Figure 22 and exploitation of 13C-NMR 
spectroscopy and 2D-NMR spectroscopy (data not shown) prove the successful coupling 







H-NMR spectrum (700 MHz, D2O, 298 K, reference: residual solvent HDO) of NKY-
CPP conjugate as structure prove. DEE=Diethylether 
 
The presence of the peaks 2 and 3 in the right circle confirms two of the protons of NKY-
80. Additionally the disappearance of peaks (left circle) that would belong to the pyridine 
of the starting material NKY-Linker 3 makes sure that the reaction worked. Acetate is 
present due to the purification using HPLC where it is used as buffer and now offers the 
counter ion for the guanidinium groups. Diethylether is present because it is used for 
precipitation after purification. Acidic protons cannot be assigned due to the exchange 
with D2O which has been used as solvent for the measurement. 
The isomeric ratio observed for product 3 was 0.4/0.6. This shifted towards 0.5/0.5, 
showing that one isomer is more reactive than the other. However, the shift difference for 
the isomers is different than before. Isomers can be assigned for proton 7 (CH pyrimidine) 
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and proton 3 (CH furan). The shift difference for the two peaks referred to proton number 
3 is small with 0.02, but similar to recorded for the conjugate with folic acid (see chapter 
3.4). The peak difference between the two peaks assigned to proton number 7 is also 
small with 0.01. In contrast to that, for the drug-linker conjugate 3, the peak difference is 
0.28, in the folic acid conjugate it is 0.26. This means, that the influence of the isomericity 
of the molecule for the conjugate with the CPP is decreased. Nevertheless, the splitting 
can be detected, assuming the presence of both isomers, E and Z. 
The mass is confirmed by MALDI-TOF-MS as displayed in Figure 23. 
 
 
Figure 23: MALDI-ToF-MS spectrum of final conjugation of NKY-80 and CPP via linker. The 
spectrum shows singly and multiply charged product and different fragments 
 
Not only the charged product ([M+H]+), but also its sodium ([M+Na]+) and potassium 
([M+K]+) adducts, as well as doubly (M+2H]2+) and triply ([M+3H]3+) charged ions are 
visible. Furthermore two fragments ([F1+H]+ and [F2+H]+) with their sodium and potassium 




Table 4: Comparison of experimental and theoretical masses measured with MALDI-ToF-MS 





Δmass [Da] Deviation [%] 
[M+H]+ 1999.42 1998.06 0.35 0.02 
[M+Na]+ 2021.39 2021.05 0.34 0.02 
[M+K]+ 2037.36 2037.16 0.20 0.01 
[M+2H]2+ 999.99 1000.04 0.05 0.005 
[M+3H]3+ 665.63 667.03 1,40 0.21 
[F1+H]+ 1669.34 1667.96 1.38 0.08 
[F1+Na]+ 1691.31 1689.94 1.37 0.08 
[F1+K]+ 1707.23 1706.05 1.18 0.07 
[F2+H]+ 1744.37 1742.0 2.39 0.14 
[F2+Na]+ 1766.36 1764.0 2.40 0.14 
[F2+K]+ 1782.33 1780.07 2.26 0.13 
 
MALDI-ToF-MS shows a relative standard deviation of 0.1 % below m/z 20,000 when 
external calibration is applied as it is the case here [72]. All measured masses are within 
the standard deviation, thus proving the successful assignment of the peaks and therefore 
the structure of the desired product. It is positive to obtain low deviations also for higher 
masses since calibration is performed with standards of masses between 600 and 
700 Da. 
MALDI-ToF-MS is a sensitive method even being able to distinguish between different 
isotopes. As displayed in Figure 24, the isotopic pattern for the molecule peak is visible. 
The m/z difference between each peak results from the different amounts of C13 carbons 




Figure 24: Isotopic pattern recorded by MALDI-ToF-MS of NKY-CPP product 4 
 
The yield of 46 % can be explained by loss during purification using HPLC and imprecise 
work-up. Peptides have a secondary structure allowing it to fold itself. It is possible that 
due to the folding some cysteine groups are in the middle of the molecule thus sterically 
hindered and consequently not capable of reacting with NKY-linker 3. Since this reaction 
is not known in literature, the yield cannot be compared to references.  
In addition to the conjugation with the above mentioned CPP, it was tried to couple 
another CPP to 3 which was not successful due to insufficient quality of the peptide. 
3.3.1 Stability test 
To prove the stability of the NKY-CPP conjugate, it was placed in an environment with 
pH 5 and degradation was followed by HPLC.  
NKY-CPP conjugate contains a hydrazone bond which ensures drug release from the 
carrier as a result of change in pH. This will occur when the conjugate enters a cell via 
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endocytosis. To confirm, that the bond will break when the conditions change, 0.4 M 
acetic acid was added to DPBS buffer to achieve a pH of ~5. To 150 µL of this solution, 
1 mg NKY-CPP was added. Subsequently, the solution was measured using HPLC under 
the same conditions as used for purification of this product. The progress was checked 
after 1, 3, 7.5 and 24 hours. During that time, the quantity of the product peak decreased 
from 96 % at t1h to 93 % at t24h, whereas another peak which is related to NKY-80 
without linker increased. The peaks were integrated to determine the quantity. The 
progress is displayed in Figure 25, showing the relative intensity of the peaks to each 
other at 280 nm. Besides NKY-CPP conjugate 4 and free NKY-80 another peak is visible 
having a similar retention time as NKY-Linker compound 3. However, since disulfide 
bonds are stable at a pH of 5 and the peak does not change in intensity, this peak is 
referred to a system peak. In case this peak arises from compound 3, it would contain a 
hydrazone which would be cleaved at the acidic conditions resulting in decreased 
intensity. 
 
Figure 25: HPLC chromatogram displaying the cleavage of NKY-80-CPP conjugate at pH 5, 
measured after 1h and 24h. X-axis: Retention time in minutes, Y-Axis: relative UV intensity 




The slow release of NKY-80 can be explained by the relatively low temperature. The 
experiment was carried out at room temperature, whereas inside the body a temperature 
of 37 °C would speed up the hydrolysis. The cleavage should be checked over a longer 
time to see if the NKY-80 is fully released. Nevertheless, the fact that NKY-80 is freed is of 
importance for the administration of this conjugation into the cell since the drug needs to 




3.4 Coupling of NKY-80-linker to folic acid 
The same NKY-linker conjugate as used in chapter 3.3 is applied for the conjugation of 
NKY-80 and folic acid, being a targeted approach for selective tissue penetration of 
melanoma cells. The conjugation between drug and folic acid was carried out as in a two-
step reaction, the general pathway is displayed in Figure 26. For the first step, a solid 
phase support using a 4-methoxytitryl resin which was preloaded with 2-aminoethanethiol 
was applied. The reactants can diffuse into the pores of the resin reacting with the 
loading. This approach simplifies the work-up since all unreacted molecules can be 
washed away. Furthermore side-reactions are limited. After successful loading the 
conjugate is cleaved with acid.  
Folic acid is added to obtain a conjugation between folic acid and cysteamine, which 
offers a free thiol which is necessary to be attached to the NKY-linker compound. This 
reaction resulted in an orange solid with a yield of 53 %. 
 
 
Figure 26: Modification of folic acid with cysteamine to introduce a thiol group and 
subsequent coupling to linker-drug conjugate 
 
According to literature data [73], only one carboxy-group reacts, which can be explained 
by sterical preferences for this or sterical hindrance for the other group. Due to the solid 
phase, a doubly addition of cysteamine is not possible because auf sterical reasons. 
Nevertheless, an attachment to the other carboxy-group would not interfere with the 
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desire as the folic acid receptor will anyhow recognize the molecule, since the pteroate 
moiety is essential for receptor binding [64]. 
The structure of FA-SH (folic acid cysteamine) 5 was not entirely confirmed by 1H-NMR 
spectroscopy, since the cysteamine protons are not doubtlessly assigned. Comparison 
with literature data proves the right allocation of the cysteamine peaks [73]. Additional 
NMR measurements (13C and 2D) were carried out to prove the structure (data not 
shown). 
ESI-ToF-MS and MALDI-ToF-MS were applied to confirm the mass. Both show [M+H]+ 
and [2M+H]+. In MALDI-ToF-MS the corresponding sodium and potassium adducts can be 
detected. 
High resolution mass spectrometry confirms the molecular formula of FA-SH 5 as 
displayed in Figure 27. 
 
 
Figure 27: High resolution mass spectrometry analysis of product 5 
 
The obtained folic acid derivative (FA-SH, 5) now offers a free thiol which can react with 
the disulfide present in the NKY-linker conjugate. The whole reaction pathway is displayed 
in Figure 26. The conjugation of folic acid derivative 5 with NKY-linker 3 resulted in an 




NMR spectra (1H and 2D measurements) of the conjugate of NKY-80 and folic acid 
confirm the structure (data not shown); also ESI-ToF-MS shows the mass of the product. 
However, ESI-ToF-MS as well as NMR spectroscopy assumes unreacted starting material 
to be present in the product. To check the purity of the compound, DOSY (diffusion-
ordered-spectroscopy) was recorded. This proves the formation of the product and refutes 
the doubts if the 1H-NMR is only a mixture of starting materials. In a DOSY measurement, 
the diffusion rate of a molecule is measured. Consequently, for each proton peak a 
diffusion rate is calculated, thus, all peaks within one molecule have the same diffusion 
rate since the whole molecule moves with the same speed. However, this measurement 
also confirms the presence of unreacted FA-SH 5, since some peaks show two diffusion 
rates thus another molecule, starting material FA-SH 5 in this case, is underlying. This 
impurity has similar properties compared to the desired product and both are difficult to 
dissolve, thus purification of the resulting solid is complicated. As in this case only 12 mg 
were obtained, column chromatography would be challenging. 
To sum up, the product is not pure and requires further purification and optimization of the 
reaction. Catalyzing the reaction with 0.3 equivalents Trifluoroacetic acid to push the 
reaction to completion and therefore avoid unreacted FA-SH 5 led to cleavage of the C=N 
bond between NKY-80 and linker. Nevertheless, the desired product was obtained but 
needs optimization in the future (see perspectives). 
 
Prior the reaction using the loaded resin described above, an unloaded resin was used as 
described by Atkinson et al. [73]. The resin was swollen in DCM, next 2-aminoethanethiol 
was dissolved and added to the resin together with pyridine. After removal of the solvent 
and washing with DCM/pyridine, the conjugation with folic acid was carried out as 
described for the preloaded resin. However, the desired product could not be obtained. 
Since folic acid lacks in solubility, the solvent amount was increased compared to the 
literature which optimized the homogeneity of the solution but still did not result in the 
product. Either the loading of the resin did not work, even though a positive ninhydrin test 
proved the presence of primary amine, or cleavage of the product was not successful. In 
order to remove the possibly formed product from the resin, the amount of TFA was 
increased from three to 50 %, also not resulting in the product. It is assumed that the 
loading was not complete due to the relatively pale blue/violet color arising after ninhydrin 
test of the resin after attachment of 2-aminoethanethiol. Ninhydrin test of the preloaded 
resin in contrast gave a dark blue/violet appearance. Both tests were not quantified, but 
judged visually. This means, that the resin has been loaded but in a relatively small 
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amount, which could not be isolated after cleavage and work-up according to the 
procedure explained in literature [73]. 
To sum up, the desired product could not be obtained by using an unloaded 4-
methoxytrityl resin, since the loading with 2-aminoethanethiol was too incomplete to 
achieve the desired product. 
 
In addition to the solid phase support, it has also been tried to carry out reactions in 
solution using different conditions.  
Referring to Zhang et al. [74], folic acid can be attached to cysteamine by forming and 
isolating the active ester of folic acid which should simplify the conjugation with 2-
aminoethanethiol. Thus, a mixture of folic acid, N-Hydroxysuccinimide (NHS), N-N'-
diisopropylcarbodiimide (DIC, coupling reagent, deviating from literature) and tiethylamine 
(TEA) was stirred for two days under argon in the dark, dissolved in DMSO. After filtration 
of a precipitate which is referred to a urea-derivative, precipitation in diethylether leads to 
a solid, which did not show the right structure in NMR spectroscopy.  
Pasut et al [75] applied a similar procedure as described by Zhang et al. However, the 
work-up procedure is slightly different, furthermore this time dicyclohexylcarbodiimid 
(DCC) is used. After the reaction was poured into diethylether for precipitation as 
suggested in literature, it was placed in the fridge where the solution turned into a gel 
making further work-up impossible. The missing formation of a urea derivative confirms 
the unsuccessful reaction. 
Another reference suggests a combination of DCC and 4-dimethylamiopyridine (DMAP) to 
form the NHS-ester of folic acid in DMSO. After stirring the mixture at 40 °C under argon 
atmosphere in a light-protected flask, a precipitate was formed which was filtered off. This 
precipitate is assigned to be a urea derivative which is always formed when working with 
DCC. Precipitation of the mixture in a cold solution of diethylether/acetone resulted in an 
orange solid. This compound shows a mass of 348.14 [M+H]+ in ESI-ToF-MS when 
expecting m/z 538.47. Also the proton NMR spectroscopy did not confirm the structure of 
the NHS-folic acid. Nevertheless, it was tried to let this compound react with cysteamine, 
since the formation of urea showed at least a progress in the reaction, although the 
structure of the product remains unknown. The reaction with cysteamine was carried out 
referring to Pinhassi et al. [76]. The unknown product, cysteamine and 
diisopropylethylamine (DIPEA) are stirred together at room temperature under argon 
atmosphere in the dark overnight in DMSO. The mixture was then poured into 
diethylether/acetone to form a precipitate which was filtered off. Even though the reaction 
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was started with 150 mg, the amount obtained was not enough for a clear NMR spectrum. 
Nevertheless, the one recorded did not show the expected peaks.  
Also a one-pot synthesis to obtain FA-SH has been carried out. Folic acid, 2-Succinimido-
1,1,3,3-tetramethyluronium-tetrafluoroborate (TSTU) and DIPEA were dissolved in DMSO. 
After stirring for 3 h, cysteamine (2-aminoethanethiol) is added. The mixture was stirred 
over night at room temperature before it was poured into cold ether to form a precipitate. 
The obtained orange solid was checked with NMR spectroscopy and ESI-ToF-MS both 
not confirming the existence of the desired product. 
To conclude, different combinations of coupling reagents and conditions for reaction and 
work-up have been tried all not resulting in the desired product. For unknown reasons the 





Within this project two final products have been synthesized. On the one hand NKY-80 
has been coupled to a cell-penetration peptide, on the other hand it is conjugated with a 
folic acid derivative.  
Prior the testing in cell-lines, the stability of the products should be tested as described in 
chapter 3.3.1 over a longer period of time and at 37 °C to see whether the hydrazone is 
cleaved at an acidic pH as it would be present in endosomes or lysosomes after 
internalization into the cell. 
Both of them should be tested in cell-tests to check their effectiveness. For the cell-tests, 
isolated immune-cells of mice and humans should be used. If effective, a murine-
melanoma-model, as well as human immune-cells and human melanoma cells will be 
applied in immunodeficient mice, to check both, the uptake as well as the release of the 
drug. They will be done in collaboration with the institute of immunology, University of 
Mainz. 
In case of NKY-CPP the potency of NKY-80 should be increased compared to free NKY-
80. The conjugate containing folic acid first needs optimization in the synthesis before a 
pure product is obtained which should also be tested in cell-tests. For this optimization it is 
suggested to use an excess of NKY-Linker to avoid the presence of unreacted FA-SH, 
which is difficult to remove from the desired product due to similar properties. Furthermore 
the reaction should be carried out in bigger scale to obtain a greater amount of product to 
be able to purify it. 
In addition to the coupling to a CPP and folic acid, NKY-80 should also be coupled to a 
suitable antibody that is also able to target regulatory T-cells and therefore also acts as 




Adenylyl cyclase (AC) is a transmembrane protein which catalyzes the formation of ATP 
(adenosine triphosphate) to cAMP (cyclic adenosine monophosphate), which is a second 
messenger involved in diverse pathways. One function is the regulation of the immune 
response, since naturally occurring regulatory T cells (nTregs) maintain the suppression of 
the immune system by contact dependent communication with the responding T cells, 
where cAMP is transferred via gap junction intercellular communication (GJIC). 
Melanoma cells overexpress cAMP and as a result the immune system is consequently 
suppressed allowing the cancer cells to proliferate in an uncontrolled way. The main aim 
of this project is to influence the activity of AC, which will decrease the level of cAMP in 
nTregs, leading to a reduced suppression of the immune response. In this approach, NKY-
80 (2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone) is applied as potent adenylyl 
cyclase inhibitor. Due to the various functions of cAMP it is crucial to attach the AC 
inhibitor to a targeting compound ensuring to only affect the malignant cells without killing 
the other healthy cells. A suitable linker that was synthesized within this project which 
enables the attachment of the drug to several carrier molecules like i) a cell-penetrating 
peptide (CPP), ii) folic acid (FA), which was carried out during this project. The linker, 
which was synthesized in gram scale in good yields, bears two functionalities, on the one 
hand a hydrazine moiety being connected to the keto-group of the NKY-80 by forming a 
hydrazone bond and on the other hand offering a disulfide for the connection to the 
different carriers. The presence of a hydrazone allows the drug to be released in 
endosomes or lysosomes due to a decrease in pH (pH 5.0-6.5 or pH 4.5-5.0 respectively) 
leading to hydrolysis of the hydrazone bond. In case of the conjugate not entering the cell 
via endocytosis thus bypassing the endosomes and lysosomes, the disulfide bond will be 
reduced by glutathione, an enzyme being present in the cytosol.  
NKY-80 was attached to a cell-penetrating peptide in milligram scale in order to increase 
the cellular uptake of NKY-80, which should enable the application of the conjugate in a 
locally administered dosage directly at the tumor side. Cell-penetrating peptides are a 
group of peptides that can cross the cell membrane by different mechanisms, either via 
endocytosis or direct penetration. However, this approach is limited to the direct injection 




Additionally, coupling to a folic acid moiety in miligramscale was carried out to enable the 
drug to affect only the quickly dividing cells, in systemic application, because they require 
a higher amount of folic acid for proliferation resulting in an increase in folic acid receptors 
on their outer membrane.  
These two different approaches are promising ways on the one hand to increase the 
potency of the drug by binding it to a CPP and on the other hand to achieve a targeted 
delivery of the drug into melanoma cells by conjugation with folic acid. 
To sum up, during this project a suitably linker with two functionalities was synthesized. 
After coupling NKY-80 to the linker via a hydrazone bond, both, a cell-penetrating peptide 
as well as a folic acid which was modified prior conjugation was attached to the linker via 
a disulfide bond. Both approaches will be tested in cell-tests in the future to check the 




Adenylylcyclase (AC) ist ein Transmembranprotein, das die Umsetzung von ATP 
(Adenosintriphosphat) zu cAMP (zyklisches Adenosinmonophosphat) katalysiert, welches 
ein sekundärer Botenstoff ist, der in diversen Signalwegen der Zelle involviert ist. Eine 
Funktion ist die Regulation der Immunantwort, da natürlich vorkommende regulatorische T 
Zellen (nTregs) die Unterdrückung des Immunsystems durch kontaktabhängige 
Kommunikation mit T Zellen regulieren, indem cAMP mittels sogenannter Gap-Junction-
vermittelter interzellulärer Kommunikation (GJIC) transferiert wird.  
Melanom-Zellen überexprimieren cAMP, woraus eine permanente Unterdrückung des 
Immunsystems resultiert, die es den Krebszellen ermöglicht, sich unkontrolliert zu 
vermehren. Die Grundidee dieses Projektes ist es, die Aktivität der Adenylatcyclase zu 
inhibiteren, was zu einer geringeren Menge an cAMP in nTregs führt und somit die 
Unterdrückung des Immunsystems gemindert wird. In diesem Ansatz wird NKY-80 (2-
Aino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone) als potenter Adenylylcyclase-Inhibitor 
verwendet. Aufgrund der vielseitigen Funktionen von cAMP ist es notwendig, den AC 
Inhibitor an ein Molekül zu knüpfen, das diesen gezielt in maligne Zellen transportiert, um 
diese zum absterben zu bringen und gesunde Zellen am Leben lässt. Ein entsprechender 
Linker wurde hierfür synthetisiert, der es ermöglicht, den Wirkstoff an verschiedene 
Trägermoleküle wie Zell-penetrierende Peptide (CPP) oder Folsäure zu kuppeln, welches 
beides während dieses Projektes durchgeführt wurde. Der Linker, der in einer 
zweistufigen Synthese im Grammmaßstab in guten Ausbeuten synthetisiert wurde, enthält 
zwei Funktionalitäten, zum einen ein Hydrazid welches mit der Keto-Gruppe des NKY-80s 
zu einem Hydrazon reagieren kann, zum anderen ein Disulfid, welches die Kupplung zu 
Biomolekülen, die Thiolgruppen wie z.B. Cysteinreste enthalten, ermöglicht. Das 
vorhandene Hydrazon stellt die Abgabe des Wirkstoffs nach Eintritt in Endosome oder 
Lysosome sicher, da der verminderte pH (5,0-6,5 bzw. 4,5-5,0) das Hydrazon hydrolisiert. 
Falls die Verbindung in die Zelle nicht über Endozytose eintritt und somit die Endosome 
und Lysosome umgeht, kann das im Zytosol vorhandene Glutathion die Disulfidbindung 
reduzieren. 
NKY-80 wurde im Miligrammmaßstab an ein Zell-penetrierendes Peptide gebunden um 
die Aufnahme in die Zelle im Vergleich zu freiem NKY-80 zu erhöhen, was somit die 
lokale Applikation direkt in den Tumor ermöglichen soll. CPP sind eine Gruppe von 
Peptiden die die Möglichkeit haben über verschiedene Mechanismen, entweder über 
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Endozytose oder direkte Penetration, in die Zelle einzudringen. Allerdings ist die Kupplung 
von NKY-80 zu einem CPP in ihrer Anwendung auf lokale Applikation limitiert, da CPPs 
nicht gezielt in Krebszellen aufgenommen werden, somit ist eine systematische Gabe 
ausgeschlossen.  
Zusätzlich wurde NKY-80 im Miligrammmaßstab an Folsäure gebunden um den Wirkstoff 
gezielt in sich schnell vermehrende Zellen einzubringen, da diese einen höheren Bedarf 
an Folsäure haben und dadurch Folsäure Rezeptoren in vermehrter Menge an ihrer 
äußeren Membran präsentieren. Diese Kombination könnte systematisch angewendet 
werden. 
Diese zwei Ansätze sind vielversprechende Wege um auf der einen Seite die Menge an 
NKY-80 in der Zelle zu erhöhen, indem es an ein CPP gebunden wird und auf der 
anderen Seite NKY-80, durch die Kupplung an Folsäure, gezielt in Melanom Zellen zu 
transportieren. 
Während dieses Projekts wurde ein Linker mit zwei Funktionalitäten hergestellt. Nach der 
Kupplung von Linker und NKY-80 durch eine Hydrazonbindung wurde sowohl ein Zell-
penetrierendes Peptid als auch eine zuvor modifizierte Folsäure über eine Disulfidbindung 





7 Experimental part 
7.1 Instruments 
NMR spectra were recorded on a Bruker Avance 250 MHz, Bruker AMX 300 MHz, Bruker 
DRX 500 MHz, Bruker Avance 700 MHz and Bruker Avance 850 MHz with the use of 
solvent proton signal as internal standard at 25 °C. 
MALDI-ToF-MS analyses were performed using a Bruker Reflex II mass spectrometer 
(Germany) operating in the reflection mode. The instrument was equipped with a nitrogen 
laser (wavelength 337 nm) and spectra were recorded using a pulse rate of 3 Hz. Ions 
were accelerated by a voltage of 20 kV and detected by a micro channel plate detector. 
Calibration was carried out before each measurement using monoisotopic masses of 
fullerenes C60 and C70 at elevated laser power.  
ESI-ToF-MS anylses were performed using a QToF Ultima 3 from micromass/waters. 
Column chromatography was performed with silica gel 0.04-0.063 mm as the stationary 
phase with analytical grad solvents. 
HPLC measurements were performed using a Jasco LC 2000 plus system equipped with 
PU-2086 Plus pumps, MD-2015 diode array detector and a ReproSil 100 C18 (250 x 
4.6 mm) column with 5 µm particle size. Eluent A was water/TEAA (v:v 97.5:2.5), eluent B 
ACN. Applied gradient started with 0.0-35.0 min 0-70 % Eluent B, continued with 35-40 
min 70-0 % Eluent B, and ended with 40-45 min 0 % Eluent B. The maximum pressure 
applied was 50.0 MPa, the injection volume was 20 µL, the measured wavelengths were 
220, 280 and 340 nm, flowrate 1 mL/min. 
Preparative HPLC was performed on the same system with a ReproSil 100 C18 (250 x 20 







Chemical Purity and additional information Supplier 
Methyl-3-
mercaptopropanoate 
98 % Sigma Aldrich 
Hydrazine monohydrate 64-65 %, reagent grade 98 % Sigma Aldrich 
1,2-di(Pyridine-2-
yl)disulfide 
98 % Alfa Aesa 
NKY-80 N/A VitasMLab, Ltd 
Peptide >80 % Genosphere 
Cysteamine  
4-methoxytrityl resin 
Loading: 0.20 – 1.30 mmol/g 
resin. 
Polymer matrix: 




PyBOP N/A Novabiochem 
DIPEA  
(N-Ethyldiisopropylamine) 
99,5 % Sigma Aldrich 
Folic acid 98 % Sigma Aldrich 





3-Mercaptopropanehydrazide (1):  
15.0 g (0.122 mol, 98 %) of methyl-3-mercaptopropanoate were 
dissolved in 20 mL methanol. 15.0 g (0.304 mol, 65%) hydrazine-
monohydrate were dissolved in 25 mL methanol and added 
dropwise to the methyl-3-mercaptopropanoate within 1 h under 
argon atmosphere and room temperature. The colorless reaction mixture was stirred over 
night at room temperature under argon atmosphere. The solvent was removed under high 
vacuum resulting in a high viscous colorless oil with a yield of 98 % (14.7 g). ESI-ToF-MS: 
m/z 239.07 [M+H]+ (disulfide), 1H-NMR (250 MHz, DMSO-d6) δ 9.05 (s, 1H, 2), 4.16 (s, 
2H, 1), 3.26-2.78 (m, 1H, 5), 2.67 (t, J = 7.0 Hz, 2H, 4), 2.32 (t, J = 7.0 Hz, 2H, 3). Rf 0.23. 
 
3-(pyridine-2-yl-disulfanyl)propanehydrazide (2):  
5.00g (22.2 mmol, 98 %) of 1,2-di(pyridine-2-yl)disulfide 
were dissolved in 30 mL Methanol. 1.36g (10.8 mmol, 
95 %) 1 were dissolved in 20 mL methanol and added to 
the solution of 1,2-di(pyridine-2-yl)disulfide dropwise 
under argon atmosphere and room temperature. The 
yellow reaction mixture was stirred over the weekend at room temperature under argon 
atmosphere. After monitoring the reaction with TLC (solvent EtoAc:MeOH 9:1) the mixture 
was purified on column chromatography (solvent: EtOAc:MeOH 9:1, silica gel, pore size 
0.04-0.063 mm) resulting in a colorless solid with a yield of 74 % (2.00 g). ESI-ToF-MS: 
m/z 230.06 [M+H]+. 1H-NMR (250 MHz, DMSO-d6) δ 9.10 (s, 1H, 2), 8.45 (ddd, J = 5.0, 
2.0, 1.0 Hz, 1H, 5), 7.88 – 7.71 (m, 2H, 8, 7), 7.24 (ddd, J = 7.0, 5.0, 1.0 Hz, 1H, 6), 4.23 








yldisulfanyl)propanehydrazide (3, NKY-Linker):  
1.05 g (4.17 mmol, 91%) 2 and 0.350 g (1.51 
mmol, 99 %) 2-amino-7-(furan-2-yl)-7,8-
dihydroquinazolin-5(6H)-one (NKY-80) were 
dissolved in 35 mL chloroform under argon 
atmosphere and room temperature. 0.01 mL 
(0.15 mmol) trifluoroacetic acid (TFA) were 
added dropwise to catalyze the reaction. The 
reaction was stirred under argon atmosphere 
at room temperature overnight. After 
monitoring the reaction with TLC (solvent: EtOAc:MeOH 9:1) showed completion of 
reaction, the solvent was almost completely removed, the precipitate was filtered off and 
dried under high vacuum resulting in a slightly yellow solid with a yield of 67 % (510 mg). 
ESI-ToF-MS: m/z 441.11 [M+H]+, 1H-NMR (700 MHz, DMSO-d6) δ 10.60 (s, 0.6H, 2’)*, 
10.44 (s, 0.4H, 2’), 8.74 (s, 0.4H, 7), 8.57 (s, 0.6H, 7)*, 8.46 (d J = 4.5 Hz, 0.6H, 5’)*, 8.40 
(d, J = 4.5 Hz, 0.4H, 5’), 7.86 – 7.74 (m, 2H, Py), 7.59 (d, J = 1.5 Hz, 0.4H, 1), 7.57 (d, J = 
1.5 Hz, 0.6H, 1)*, 7.24 (m, 0.6H, Py)*, 7.18 (m, 0.4H, Py), 7.01 (s, 0.8H, 8), 6.97 (s, 1.2H, 
8)*, 6.39 (dd, J = 3.0, 1.5 Hz, 0.4H, 2), 6.38 (dd, J = 3.0, 1.5 Hz, 0.6H, 2)*, 6.17 (d, J = 3.0 
Hz, 0.4H, 3), 6.15 (d, J = 3.0Hz, 0.6H, 3)*, 3.15 – 2.53 (m, 9H). Rf value: 0.57. *=Signals 
of major isomer 
 
NKY-Linker-Cys-Gly-Gly-Trp-(Arg)8*8Ac (4):  
5 mg (10.0 µmol, 88 %) of 3 was dissolved in 3 mL DMF. 44 mg (17.03 µmol, 80 %) of the 
peptide CGGWRRRRRRRR*8TFA (amidated C-terminus) were dissolved in 1 mL DPBS 
buffer (Dulbecco’s phosphate buffered saline) and added to the solution at room 
temperature dropwise. The reaction was monitored using HPLC (solvent:97.5% 
H2O/2.5 % TEAA:ACN, column: C-18). After disappearance of 3 after 2h, the mixture was 
purified using preparative HPLC. The combined fractions were lyophilized, the crude was 
dissolved in 1 mL methanol and poured into 100 mL diethylether resulting in a colorless 
solid with a yield of 46 % (12.0 mg) and a purity of 96 %. MALDI-ToF-MS: m/z 1999 




0.5/0.5: 1H-NMR (700 MHz, D2O) δ 8.70 (s, 0.5H, 7), 8.69 (s, 0.5H, 7), 7.35 (s, 1H, 1), 
7.29 (d, J = 8.0 Hz, 1H, 20), 7.26 (dd, J = 8.0, 4.0 Hz, 1H, 23), 7.16 (d, J = 11.5 Hz, 1H, 
25), 7.04 (m, 1H, 21), 6.92 (m 1H, 22), 6.30 – 6.27 (dd, J = 3.0, 1.5 Hz, 1H, 2), 6.01 (d, J = 
3.0 Hz, 0.5H, 3), 6.00 (d, J = 3.0 Hz, 0.5H, 3), 4.38 (m, 1H, 18), 4.28 – 4.19 (m, 7H, 27), 
4.11 (m, 1H, 27), 3.92 – 3.72 (m, 5H, 11, 13, 16), 3.16 – 2.62 (m, 25H, 30, 19, 9, 3’, 4’, 4, 
6, 5), 1.81 – 1.35 (m, 32H, 28, 29).  
 
2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-((2-
mercaptoethyl)amino)-5-oxopentanoic acid*TFA (5): 
0.393 g (173 µmol, loading: 0.44 mmol/g) of a 4-methoxytrityl resin preloaded with 2-
aminoethanethiol were swollen in 8 mL dichloromethane (DCM) for 30 minutes. After the 
solvent was removed, a solution of 382 mg (857 µmol, 99 %) folic acid and 450 mg (865 
µmol, 95 %) PyBOP dissolved in 10 mL DMSO is added. Afterwards 412 µL (2.41 mmol, 
99.5 %) diisopropylethylamine (DIPEA) is added dropwise. The reaction was shaken over 
night at 40 °C in the oven. After removal of the solvent, the resin was washed with DMSO, 
DMF, DCM and methanol (5x10 mL each). A negative Ninhydrin test of the resulting resin 
proved no primary amine being present anymore. For cleaving the product from the resin, 
8 mL TFA/DCM (v:v 1:1) is added. The mixture is shaken for 1 h at room temperature. 
The removed orange solution is poured into 400 mL diethylether to precipitate the product. 
62.3 mg of an orange solid are obtained with a yield of 53 % (62.3 mg). ESI-ToF-MS: m/z 





1H-NMR (300 MHz, DMSO-d6) δ 8.68 (d, J = 1.0 Hz, 1H, 23 (long range with 17 assigned 
by 2D measurement), 8.11 – 7.88 (m, 2H, 1, 8), 7.66 (dd, J = 9.0, 3.0 Hz, 2H, 11/15), 7.44 
(broad, 3H, 26, 29), 6.62 (dd, J = 9.0, 1.0 Hz, 2H, 12/14), 4.52 (s, 2H, 17, coupling to 23 
assigned by 2D measurement), 4.38 – 4.23 (m, 1H, 7), 3.59 – 3.50 (m, 1H, 16), 3.28 – 
3.08 (m, 2H, 2), 2.45 – 1.76 (m, 6H, 5, 6, 34). Furthermore the molecular formula is 




oxopropyl)disulfanyl)ethyl)amino)-5-oxopentanoic acid (6):  
26.4 mg 3 (52.7 µmol, 88 %) were dissolved in 1 mL DMSO. 27 mg 5 (39.6 µmol, 90 %) 
were dissolved in 2 mL DMSO separately and added dropwise to the solution of 3 within 2 
minutes. The yellow reaction mixture was stirred at room temperature for 1 day. 
Precipitation of the product in 50 µL diethylether resulted in an orange powder with a yield 
of 22 % (12.0 mg) and a purity of 60 %. The product was not further purified. ESI-ToF-MS: 




1H-NMR (300 MHz, DMSO-d6) δ 11.36 (d, J = 34.1 Hz, 1H, 32), 10.58 (s, 0.6H, 40)*, 
10.43 (s, 0.4, 40), 8.75 (s, 0.6H, 52)*, 8.57 (s,0.4H, 52), 8.64 (s, 1H, 23), 8.01 (m, 2H, 2 
NH, 1, 8), 7.79 (s, 1H, 26), 7.70 – 7.57 (m, 3H, 11, 15, 56), 6.98 (broad, 4H,29, 58), 6.64 
(d, J = 9.0 Hz, 2H, 12, 14), 6.38 (m 1H 55), 6.16 (m, 1H, 56 ArH), 4.48 (d, J = 5.0 Hz, 2H, 
17), 4.32 (m, 1H, 7), 3.56 (d, J =5.0 Hz, 1H, 16), 2.90 – 1.77 (m, overlapping with solvent, 
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